Evidence map›Paper›PMID 27329199›Full record

ReviewJournal of gynecologic oncology2016

Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research.

Sung Jong Lee, Andrew Yang, T C Wu, Chien Fu Hung

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of gynecologic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 145 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Sung Jong LeeDepartment of Obstetrics and Gynecology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.ORCID http://orcid.org/0000-0002-6077-2649
Andrew YangDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-0200-9140
T C WuDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-1623-4584
Chien Fu HungDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-9170-7797
Johns Hopkins University · USThe Catholic University of Korea St. Vincent's Hospital · KR

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI Richard Bruce Roden · 2003 to 2026
$53.5M
ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITYR01CA114425 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2005 to 2016
$3.0M
Molecular pathogenesis and host response following persistent E6/E7 expressionR21AI109259 · NIAID · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2014 to 2015
$446k
Innovative Strategy to Generate Antigen-Specific Cytotoxic LymphocytesR21CA194896 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2015 to 2016
$388k
NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA114425NCI NIH HHS R21 CA194896NIAID NIH HHS R21 AI109259
6 · The paper itself

Abstract

Cervical cancer is the fourth most lethal women's cancer worldwide. Current treatments against cervical cancer include surgery, radiotherapy, chemotherapy, and anti-angiogenic agents. However, despite the various treatments utilized for the treatment of cervical cancer, its disease burden remains a global issue. Persistent infection of human papillomavirus (HPV) has been identified as an essential step of pathogenesis of cervical cancer and many other cancers, and nation-wide HPV screening as well as preventative HPV vaccination program have been introduced globally. However, even though the commercially available prophylactic HPV vaccines, Gardasil (Merck) and Cervarix (GlaxoSmithKline), are effective in blocking the entry of HPV into the epithelium of cervix through generation of HPV-specific neutralizing antibodies, they cannot eliminate the pre-existing HPV infection. For these reason, other immunotherapeutic options against HPV-associated diseases, including therapeutic vaccines, have been continuously explored. Therapeutic HPV vaccines enhance cell-mediated immunity targeting HPV E6 and E7 antigens by modulating primarily dendritic cells and cytotoxic T lymphocyte. Our review will cover various therapeutic vaccines in development for the treatment of HPV-associated lesions and cancers. Furthermore, we will discuss the potential of immune checkpoint inhibitors that have recently been adopted and tested for their treatment efficacy against HPV-induced cervical cancer.

Indexed as

ImmunotherapyTranslational Research, BiomedicalDendritic CellsFemaleGenetic VectorsHumansPapillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsVaccines, DNAVaccines, SubunitPapillomavirus VaccinesVaccines, DNAVaccines, SubunitHuman PapillomavirusImmune Checkpoint InhibitorImmunotherapyTherapeuticsUterine Cervical NeoplasmsVaccines

Identifiers

PMID27329199
PMCPMC4944018
OpenAlexW2465413281

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.